The SARAH Domain of RASSF1A and Its Tumor Suppressor Function by Dittfeld, Claudia et al.
Hindawi Publishing Corporation
Molecular Biology International
Volume 2012, Article ID 196715, 10 pages
doi:10.1155/2012/196715
Research Article
The SARAH Domain of RASSF1A and Its
Tumor Suppressor Function
ClaudiaDittfeld,1,2 AntjeM. Richter,3 Katrin Steinmann,1,3
AntjeKlagge-Ulonska,1 and ReinhardH.Dammann1,3
1AWG Tumor Genetics of the Medical Faculty, Martin-Luther-University Halle-Wittenberg, 06108 Halle, Germany
2OncoRay, National Center for Radiation Research in Oncology, Medical Faculty Carl Gustav Carus, University of Technology,
06108 Halle, Dresden, Germany
3Institute for Genetics, Justus-Liebig University Giessen, 35392 Giessen, Germany
Correspondence should be addressed to Reinhard H. Dammann, reinhard.dammann@gen.bio.uni-giessen.de
Received 16 November 2011; Revised 1 February 2012; Accepted 2 February 2012
Academic Editor: Geoﬀrey J. Clark
Copyright © 2012 Claudia Dittfeld et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The Ras association domain family 1A (RASSF1A) tumor suppressor encodes a Sav-RASSF-Hpo domain (SARAH), which is an
interaction domain characterized by hWW45 (dSAV) and MST1/2 (dHpo). In our study, the interaction between RASSF1A and
RASSF1CwithMST1andMST2wasdemonstratedanditwasshownthatthisinteractiondependsontheSARAHdomain.SARAH
domain-deleted RASSF1A had a similar growth-reducing eﬀect as full-length RASSF1A and inhibited anchorage independent
growth of the lung cancer cell lines A549 signiﬁcantly. In cancer cells expressing the SARAH deleted form of RASSF1A, reduced
mitotic rates (P = 0.001) with abnormal metaphases (P<0.001) were observed and a signiﬁcantly increased rate of apoptosis was
found(P = 0.006)comparedtofull-lengthRASSF1A.Althoughtheassociationwithmicrotubulesandtheirstabilizationwasunaf-
fected, mitotic spindle formation was altered by deletion of the SARAH domain of RASSF1A. In summary, our results suggest that
the SARAH domain plays an important role in regulating the function of RASSF1A.
1.Introduction
The Ras association domain family 1 gene (RASSF1) was
identiﬁed on chromosome 3p21.3, a region frequently delet-
ed in cancer [1]. There are two major transcripts of RASSF1,
termed RASSF1A and RASSF1C, which are transcribed
from diﬀerent CpG island promoters [1]. The promoter of
RASSF1A is often hypermethylated in cancer, whereas the
promoterregionofRASSF1C isnevermethylated[2,3].Both
isoforms encode a Ras association domain in the C-ter-
minus, an ATM-kinase phosphorylation site, a SARAH
protein interaction domain, and the N-terminal sequence of
RASSF1A harbors a diacyl glycerol binding domain [1, 4].
It has been demonstrated that RASSF1A encodes a tumor
suppressor gene, which reduces tumor growth in vivo and
in vitro [1, 5–8]. Deletion of Rassf1a in mice signiﬁcantly
increased spontaneous and induced tumorigenesis [9–11]. It
has been reported that RASSF1A binds to microtubules and
protects cells from microtubule destabilizing agents [7, 12–
15]. This interaction contributes to cell cycle regulation and
mitotic progression.
RASSF1A is regulated by the binding of RAS and the
novelRaseﬀector1(NORE1)andmediatesproapoptoticsig-
nals through binding of the mammaliansterile 20-like kinase
1a n d2( M S T 1a n dM S T 2 )[ 16–19]. Moreover, an associ-
ation of RASSF1A with the BH3-like protein modulator of
apoptosis was observed and this interaction regulates con-
formationalchangeofBAXandapoptosis[20,21].RASSF1A
promotes MDM2 self-ubiquitination and prevents p53 deg-
radation [22]. Additionally, it was reported that RASSF1A
inhibits the anaphase promoting complex (APC) through its
binding to CDC20 and induces mitotic arrest by stabilizing2 Molecular Biology International
mitotic cyclins [23] and it was further shown that the Aurora
mitotic kinases are involved [24]. However, we were not able
to verify the interaction between RASSF1A and CDC20 [25].
In the C-terminal part of RASSF1A and RASSF1C, a
protein-protein interaction domain called SARAH (Sav/
RASSF/Hpo)hasbeendetermined[26].TheSARAHdomain
is a key feature of the Hippo signaling pathway components,
by which the interaction of Sav, Rassf, and Hpo is accom-
plished [26]. In the Drosophila Hippo pathway, Salvador
(Sav, the human homologue is named WW45) acts as a
scaﬀold protein that interacts with the proapoptotic kinase
Hippo (Hpo, human homologue MST) [27–29]. Hpo is
able to phosphorylate the kinase Warts (human homologue
LATS), which in Drosophila leads to cell cycle arrest and
apoptosis [28–30].
It was shown that the single Drosophila orthologue of the
human RASSF proteins restricts Hpo activity by competing
with Sav for binding to Hpo [31]. Praskova et al. previously
showed that human RASSF1A interacts with MST1 through
the C-terminus [16] and more precisely through the SARAH
domain [32].MST1 has two caspase 3 cleavagesites and both
MST1 and MST2 play a role in processes of apoptosis both
before and after caspase cleavage [33]. The cleaved form of
MST1translocatesinthenucleusandphosphorylateshistone
H2B at Ser14 [34, 35]. H2B phosphorylation correlates with
apoptotic chromatin condensation and nuclear fragmenta-
tion in mammalians and yeast [35, 36]. Following death re-
ceptor activation, MST1 (homologue of Hpo) is known to
become activated through caspase-dependent cleavage [19].
The cleaved fragment then localizes from the cytoplasm to
the nucleus, where it induces apoptosis [19]b yc h r o m a t i n
condensation through activation of the c-Jun N-terminal
kinase pathway [37].
Both RASSF1A and WW45 activate MST2 by promoting
its autophosphorylation [38]. Moreover, RASSF1A stabilizes
MST1/2 activation by preventing the dephosphorylation of
these kinases [39]. Activated MST1/2 phosphorylates diﬀer-
ent targets including LATS kinases, which in turn activate
the transcription coactivator YAP1 [40, 41]. Other MST1/2
targets are H2AX [42], FOXO [43], and troponin [44].
To gain new insights into the tumor suppressor function
of RASSF1A, we deleted its SARAH domain and analyzed its
altered function. Deletion of the SARAH domain resulted in
a decreased colony formation of tumor cells. During mitosis,
abnormal spindle formation was observed. We demonstrate
that the interaction of RASSF1A and RASSF1C with MST1
and MST2 depends on the SARAH domain. Deregulation of
the SARAH domain may contribute to altered proapoptotic
and mitotic signaling of RASSF1A.
2.MaterialsandMethods
2.1. Tissues and Cell Lines. The localization experiments
and the protein expression experiments were performed in
HEK293 and COS7 cells (ATCC, Manassas, Virginia, USA).
Forstabletransfection,thelungcancercelllineA549(ATCC)
was used. A549 cells harbor epigenetic silenced RASSF1A,
but express RASSF1C [1].
2.2. Interaction Studies Using the Yeast Two-Hybrid System.
The Matchmaker Two-hybrid system (Clontech, Mountain
View, USA) was utilized. cDNAs of RASSF1A and
RASSF1C were described previously [1]. The genes MST1
and MST2 were cloned after ampliﬁcation of the frag-
ments from EST-clones IRAKp961C0282Q and
IRAKp961I0613Q (RZPD, Berlin, Germany), respectively.
RASSF1AΔSARAH and RASSF1A were cloned into the
vector pGADT7, RASSF1C and RASSF1CΔSARAH into
the vector pAS2-1, and MST1 and MST2 into pGBKT7
[25, 45]. Mutant forms of RASSF1 were generated with the
QuickChange XL Site-Directed Mutagenesis Kit (Strata-
g e n e ,L aJ o l l a ,U S A )a n df o r w a r dp r i m e r( 5  -
AGGAAAATGACTCTGGGCCCCTTGGGTGACCTCT) and
the complementary reverse primer. All constructs were
conﬁrmed by sequencing. The yeast strain PJ69-4A was co-
transformed with 0.1μg of each plasmid using the PEG/LiAc
method. The interaction analysis was carried out on SD
minimal medium plates without adenine and histidine and
the transformation eﬃciency was controlled on SD plates
with adenine and histidine. The strength of interaction was
investigated by quantiﬁcation of the expression of the β-gal-
actosidase reporter gene with o-nitrophenyl-β-D-galacto-
pyranoside (ONPG) as substrate at 420nm.
2.3. Interaction Studies by Coprecipitation. MST1 and MST2
were cloned into the vector pCMV-Tag1 (Stratagene, La
Jolla, USA) and/or in the vector pEBG. To investigate the in-
teraction of speciﬁc RASSF1 forms, MST1 and MST2, co-
transfections (Lipofectamine 2000, Invitrogen, Carlsbad,
USA) were performed in HEK293 cells. Plasmids (pEBG and
pCMV-Tag 1) were used, that express GST-Flag-RASSF1A,
GST-Flag-RASSF1C, GST-Flag-RASSF1AΔSARAH, GST-
Flag-RASSF1CΔSARAH, and GST or Flag-MST1, Flag-
MST2, and Flag-WW45 [45]. Two days after transfection,
total protein was extracted in RIPA buﬀer. The GST-fused
proteins were precipitated with glutathione-sepharose (Am-
ersham Biosciences, Freiburg, Germany). Samples were sep-
arated on a 10% PAGE gel and blotted. The interaction was
determined with anti-Flag-antibodies (F3165, Sigma, Stein-
heim,Germany)andanti-GSTantibodies(SantaCruz,Santa
Cruz, USA).
2.4. MST1 and MST2 Phosphorylation. A549 were treated
with 3μM staurosporine for 3h or transfected with 10μgo f
constructs with Turbofect for 36h (Fermentas, St. Leon-Rot,
Germany). Total protein was isolated using Flag-lysis buﬀer,
samples were denatured with Laemmli-buﬀer, separated in
10% SDS-PAGE, and blotted onto PVDF membranes. First
antibodies are: anti-GAPDH (FL332 Santa Cruz, USA), anti-
P-MST1 (Thr183)/MST2 (Thr180) (#3681 Cell signaling,
Frankfurt, Germany), anti-Flag (F3165 Sigma, Steinheim,
Germany), and secondary antibodies are HRP coupled
(sc2004/5 Santa Cruz, USA). ECL (WBKLS0100 Millipore,
Schwalbach, Germany) was used for detection with Versadoc
(Bio-Rad, M¨ unchen, Germany).Molecular Biology International 3
2.5. Generation of Stable Transfected Cell Lines. RASSF1A,
RASSF1AΔSARAH, and RASSF1C were cloned into the vec-
tor pCMV-Tag1 (Stratagene, La Jolla, USA). The lung cancer
cell line A549 was transfected using Lipofectamine 2000 (In-
vitrogen, Carlsbad, USA). Colonies were selected under
1mg/mL Geneticin (Gibco, Karlsruhe, Germany) in DMEM
and clones were picked after 4 weeks. Expression of
Flag-RASSF1 was conﬁrmed by RT-PCR using the FLAG-
speciﬁc primer (5 -TGGATTACAAGGATGACGACG)
and RASSF1-speciﬁc primer L27111 (5 -
TCCTGCAAGGAGGGTGGCTTC). PCR products were an-
alyzed on a 2% Tris-borate EDTA agarose gel.
2.6. Proliferation Analyses of Stable Transfected Cell Lines.
Growth curves of stable transfected clones were analyzed by
seeding 150,000 cells in triplicates in 6-well plates. Every 24
hours, cells were counted using a Neubauer counting cham-
ber.Inordertoinvestigatetheproliferationinsoftagar,stable
transfected cells were seeded in 0.3% agarose. Experiments
were performed in duplicates with 5,000 cells per plate under
selectionwith1mg/mLGeneticin.Colonysizewasmeasured
after 4 weeks with a microscope (LEICA DMIRB, Wetzlar,
Germany). Therefore, colonies were stained with 400μLo f
5mg/mL INT and the size of 25 colonies was determined
with MetaVue (Molecular Devices GmbH, Ismaning, M¨ un-
chen).
2.7. Localization Studies. RASSF1A and RASSF1C were
cloned into the ﬂuorescence vector pEYFP-C2 (Clontech,
Mountain View, USA). The deletion of the SARAH domain
of RASSF1A and RASSF1C was accomplished by the Quick-
Change XL Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, USA) with the upper SARAH deletion primer 5 -
AGGAAAATGACTCTGGGCCCCTTGGGTGACCTCT and
the complementary lower primer. After transient transfec-
tion into HEK293 cells with Lipofectamine 2000 (Invitrogen,
Carlsbad, USA), the localization of YFP-RASSF1A, YFP-
RASSF1AΔS, YFP-RASSF1C, and the vector control were
investigated with a ﬂuorescence microscope. Cells were co-
stained with anti-α-tubulin (Molecular Probes, Invitrogen,
Carlsbad, USA) antibodies and Alexa Fluor goat anti-mouse
(Molecular Probes, Invitrogen, Carlsbad, USA) antibodies to
show the colocalization with the microtubules and spindle
poles, respectively. Nuclei of the cells were visualized by
staining with DAPI (0,1μg/mL in PBS). Cells in mitoses were
scored by microscopy (ZEISS Axioplan 2). Cells with highly
condensed chromosomes and spindle structures were clas-
siﬁed as mitotic cells. For microtubule stability analysis, the
cellsweretreatedonedayaftertransfectionforonehourwith
20μM nocodazole, ﬁxed, and stained with DAPI and anti-α-
tubulin antibodies. YFP constructs are shown in green color.
2.8. Apoptosis Analysis by TUNEL Staining. The lung can-
cer cell line A549 was transiently transfected with diﬀer-
ent RASSF1A constructs tagged with yellow ﬂuorescence
(pEYFP-C2)usingLipofectamine2000(Invitrogen,Carlsbad,
USA).Aftertwodays,thetransfectedcellswereharvestedand
centrifuged on a slide. After ﬁxation with formaldehyde, a
TUNEL staining was performed with the In Situ Cell Death
Detection Kit, TMR red (Roche, Mannheim, Germany).
The nuclei were costained with DAPI (0,1μg/mL) solution.
Slideswerequantiﬁedwithaﬂuorescencemicroscope(ZEISS
Axioplan 2). Yellow ﬂuorescence expressing cells (500) were
countedandtherateofapoptotic cells(redﬂuorescence)was
calculated. All experiments were done in triplicates.
2.9. Statistical Analysis. All statistical evaluations were per-
formedusingtheSPSS12.0Software(SPSSScience,Chicago,
IL). A Probability of P<0.05 was considered as signiﬁcant.
3. Results
3.1. The RASSF1-SARAH Domain Binds MST1 and MST2.
In silico analysis of RASSF1A (340 aa) and RASSF1C (270
aa) by PROSITE (www.expasy.org) revealed the presence of a
Sav-RASSF-Hpo (SARAH) domain at their C-terminus (290
to 337 and 220 to 267, resp.) (Figure 1(a)). To gain insight
into the function of the SARAH domain of RASSF1, the
interaction of RASSF1A, RASSF1C, RASSF1AΔSARAH, and
RASSF1CΔSARAH with MST1 and MST2 was investigated
in the yeast two-hybrid system (Figures 1(b) and 1(c)).
Both RASSF1 isoforms (RASSF1A and RASSF1C) interacted
with MST1 and MST2, but when the SARAH domain was
deleted the proteins were not able to interact anymore. These
interactions were quantiﬁed in an o-nitrophenyl-β-D-galac-
topyranoside (ONPG) assay (Figure 1(c)). The interaction of
RASSF1A and RASSF1C with MST1 and MST2 was veriﬁed
by coprecipitation experiments (Figure 1(d) and data not
shown). The interaction between RASSF1A and MST1 and
MST2 was conﬁrmed (Figure 1(d)). There was also an inter-
action between RASSF1C and MST1 and MST2 (data not
shown). Interaction of RASSF1A and RASSF1C with MST1
and MST2 was abolished, when the SARAH domain was
deleted (Figure 1(d) and data not shown).
3.2.RASSF1AConstructswithDeletionoftheSARAHDomain
InhibitCellGrowth. GrowtheﬀectsoftheSARAHdomainof
RASSF1 were investigated in stable transfected lung cancer
cells. The lung cancer cell line A549 was transfected with
RASSF1A, RASSF1C, and RASSF1AΔS, and the control
vector (pCMV-Tag1) and the growth of these cells were
evaluated (Figure 2). A549 harbor epigenetically silenced
RASSF1AbutexpressRASSF1C.Wepickedstabletransfected
colonies and expression of RASSF1-speciﬁc forms was
conﬁrmedbyRT-PCR(Figure 2(a)). Subsequently,the proli-
feration- and anchorage-independent growth of these clones
was analyzed. Proliferation of RASSF1A expressing cells was
signiﬁcantly reduced at 96h compared to RASSF1C express-
ing cells and control cells (P = 0.022 and P = 0.007, resp.).
Two RASSF1AΔS expressing clones showed a similar growth
to RASSF1A expressing cells. RASSF1AΔS clone1 and clone2
had a signiﬁcant reduction of growth at 96h compared to
RASSF1C (P = 0.027 and 0.042, resp.) and controls (P =
0.018 and 0.029, resp.). Subsequently, the anchorage inde-
pendent growth was determined in soft agar experiments4 Molecular Biology International
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Figure 1: Binding studies of RASSF1, MST1, and MST2. (a) Characteristic domains of RASSF1 isoforms and SARAH deletion (ΔS) mutants
are the protein kinase C conserved region (C1; blue), the ATM-kinase phosphorylation site (black), Ras-association (RalGDS/AF-6) domain
(RA; yellow), and the Sav-RASSF-Hpo interaction site (SARAH; red). (b) Interaction analysis using the yeast two hybrid system. The
indicated constructs were cotransformed into yeast strain PJ 69-4A. Interaction was evaluated on SD plates without alanine and histidine
(interaction plate). Transformation was controlled on SD plates with alanine and histidine (control plate). (c) Quantitative interaction
analysis using the ONPG assay. In three independent colonies, the activation of the β-galactosidase reporter gene was quantiﬁed with ONPG
assubstrate.Thestandarddeviationisindicated.(d)Bindingstudiesincoprecipitation.ConstructsthatexpressGST(a),GST-Flag-RASSF1A
(b), GST-Flag-RASSF1AΔS (c), Flag-MST1 (d), or Flag-MST2 (e) were transfected into HEK293 cells. After two days, total protein was
extracted and GST-tagged proteins were precipitated with glutathione sepharose. Samples were separated on a 10% PAGE gel and blotted.
The precipitated and coprecipitated proteins were determined with anti-Flag-antibodies and anti-GST antibodies.
(Figures 2(c) and 2(d)). In these experiments, cells express-
ing RASSF1AΔS (clone1) exhibited a signiﬁcantly reduced
colony growth (average colony size: 22μm) compared to
RASSF1A(average:36μm;P<0.01,Welch’stest)andcontrol
(average: 66μm; P<0.01, Welch’s test).
3.3. Expression of RASSF1A with a Deleted SARAH Do-
main Induces Aberrant Mitosis and Apoptosis. We trans-
fected yellow ﬂuorescent protein-tagged RASSF1A and
RASSF1AΔSARAH (RASSF1AΔS) into HEK293 and COS7
cells and the localization was determined by ﬂuorescence
microscopy (Figure 3(a)). RASSF1A and RASSF1AΔSa r e
both localized at the tubulin-containing cytoskeleton during
interphase. In mitotic cells, RASSF1A and RASSF1AΔSw e r e
detected at spindles and centrosomes (Figure 3(a)). In the
RASSF1AΔS expressing HEK293 cells, multipolar spindles
and unequal alignment of the chromosomes between poles
wereobserved(Figure 3(a)).InCOS7cells,overexpressionof
RASSF1AΔS also induced monopolar spindles (Figure 3(a)).
Interestingly,mitotic rateofRASSF1AΔSexpressing cellswas
signiﬁcantly (P = 0.001) reduced to 3.4% compared to 8.6%
in RASSF1A transfected HEK293 cells (Figure 3(b)). The
mitotic rate in vector transfected cells was 1.2% (data not
shown). The majority (74.3%; P<0.001) of mitoses in
RASSF1AΔS expressing cells were abnormal (multi- or mo-
nopolar) comparedtoRASSF1Atransfectedcells,whereonly
0.6% of abnormal mitosis were counted (Figure 3(c)).
To determine if the aberrant spindle formation in
RASSF1AΔS expressing cells is due to an altered microtubule
stability of these cells, transiently transfected cells were
treatedwith20μMnocodazoleforonehour(Figure 4(a)).In
YFP control cells, this treatment caused massive depolymeri-
sation of the microtubules in interphase and during mitosis.
RASSF1A, RASSF1AΔS, and RASSF1C overexpressing cells
wereabletostabilizemicrotubulesfromdepolymerizationby















































































































Figure 2: Proliferation analysis of RASSF1AΔSARAH expressing lung cancer cells. (a) A549 lung cancer cells were transfected with pCMV-
Tag1, RASSF1A, RASSF1C, and RASSF1AΔSARAH (RASSF1AΔS) and stable clones were analyzed. RASSF1 expression of clones was
conﬁrmed by RT-PCR using a Flag-speciﬁc forward primer and primer L27111. Products (RASSF1A and RASSF1AΔS, 585bp; RASSF1C,
374bp) were analysed with controls (pCMV-Tag1 and H2O) and a 100bp ladder (M) on a 2% Tris-borate EDTA agarose gel. (b) Growth
curve of A549 cells stably transfected with the indicated constructs. Clones were analyzed by seeding 1.5×105 cells in 6-well plates. Every 24
hours, cells were counted using a Neubauer chamber. Three independent experiments were performed and the mean and standard deviation
is plotted. (c) Colony sizes in a soft agar experiment after 4 weeks. Examples of colonies expressing pCMV-Tag1, RASSF1A, and RASSF1AΔS
are shown. (d) 25 colonies were measured and the average colony size was calculated. Statistical signiﬁcance P-values are indicated.
To analyze the eﬀect of the deletion of the SARAH
domain on the proapoptotic function of RASSF1A, a tran-
sient transfection into the lung cancer cell line A549 was
performed and the rate of transfected and apoptotic cells
was calculated after 1 to 2 days (Figure 4(b)). Apoptotic cells
were stained using red ﬂuorescence TUNEL-Kit and YFP was
used as a control. The rate of apoptosis was signiﬁcantly
(P = 0.001)higher,whenthecellsexpressedRASSF1A(28%)
in comparison to RASSF1C (16%) and the YFP control
(14%, Figure 4(b)). The deletion of the SARAH domain
(RASSF1AΔS) resulted in a signiﬁcantly increased apop-
totic rate of 39% compared to RASSF1C (P<0.001) and
RASSF1A (P = 0.006, Figure 4(b)). In summary, our results
show that expression of RASSF1A with a deletion of the
SARAH domain deregulates normal mitotic progression and
enhances apoptosis.
Subsequently, RASSF1A-induced autophosphorylation
of MST1 and MST2 was analyzed in A549 lung cancer cells
(Figure 5). For this propose, we have utilized an antibody
that detects endogenous MST1 and MST2 only when phos-
phorylated at Thr183 and Thr180, respectively. Treatment of
A549cellswith3μMstaurosporineinducedphosphorylation
of MST1 and MST2 (Figure 5), as described previously
[34, 46]. However, when A549 cells were transfected with
RASSF1AandRASSF1AΔSARAH,phosphorylationofMST1




















































































Figure 3: Eﬀects of RASSF1AΔSARAH expression on mitosis. (a) HEK293 and COS7 cells were transfected with YFP-RASSF1A and YFP-
RASSF1AΔSARAH (RASSF1AΔS) and stained using DAPI and anti-α-tubulin antibody. Yellow ﬂuorescent is shown in green. (b) Rate of
mitosis in HEK293 after transient expression. Cells with highly condensed chromosomes and spindle structures were classiﬁed as mitotic
cells (c) Abnormal mitoses (monopolar, multipolar spindles and abnormal spindle ﬁbers) were counted in HEK293 cells and the rate of
abnormal mitosis is plotted. All experiments were done in triplicates and 500 cells each were evaluated. The mean and standard deviation

































































Figure 4: (a) Microtubule stability of RASSF1AΔSARAH expressing mitotic cells. HEK293 cells were transfected with plasmids YFP,
YFP-RASSF1A or YFP-RASSF1AΔSARAH (YFP-RASSF1AΔS). One day after transfection, the cells were treated for one hour with 20μM
nocodazole, ﬁxed and stained with DAPI and anti-α-tubulin antibodies. Yellow ﬂuorescence is shown in green. (b) Induction of apoptosis
aftertransientexpressionofRASSF1AandRASSF1AΔSARAH.LungcancercellsA549weretransfectedwithYFP,YFP-RASSF1C(RASSF1C),
YFP-RASSF1A (RASSF1A), and YFP-RASSF1AΔSARAH (RASSF1AΔS). TUNEL staining was utilized to determine the frequency of
apoptotic cells in transfected cells. All experiments were done in triplicates and the mean and standard deviation were determined. Statistical
signiﬁcant P-values are indicated.
obtained in HEK293 cells (data not shown). Praskova et al.
showed that the MST1 kinase autoactivation through phos-
phorylation is inhibited by coexpression of RASSF1A and
RASSF1C [16].
4. Discussion
RASSF1A is a tumor suppressor gene, which is involved in
several signaling pathway including apoptosis, microtubule
stability, proliferation, and mitotic regulation [2, 3]. In our
study, we have analyzed the function of the Sav-RASSF1-
Hpo (SARAH) domain of RASSF1A. Here, we report that
the SARAH domain regulates several pathways, which are
frequentlyalteredintumors.TheSARAHdomainisinvolved
in apoptosis and growth-suppressing functions of RASSF1A
like anchorage-independent proliferation. Moreover, the
SARAH domain is important for mitotic progression and
spindle formation. It has been previously reported that
RASSF1 interacts through its C-terminal domain with MST1
andtherebyregulatesMST1-mediatedapoptosis [16,18,19].
We demonstrate that RASSF1A and RASSF1C interact with
both MST1 and MST2. This complex may regulate several
pivotal signaling pathway including apoptosis and phospho-
rylationofWarts/LATSserinethreonine kinasesthatregulate
mitotic progression.
It has been reported that RASSF1A regulates a proapop-
totic pathway through its interaction with the proto-onco-





























































































Figure 5: Phosphorylation of MST1/2 is induced by staurosporine.
A549 were treated with 3μM Staurosporine for 3h. For trans-
fections Turbofect (Fermentas) was used with 10μg of indicated
constructsfor36h.TotalproteinwasisolatedusingFlag-lysisbuﬀer,
samples were denatured with Laemmli-buﬀer, separated in 10%
SDS-PAGE and blotted onto PVDF membrane. First antibodies
are: α-GAPDH, α-P-MST1 and α-Flag and secondary antibody are
HRP coupled (sc2004 and sc2005 Santa cruz). ECL (WBKLS0100
Millipore) was used for detection with Versadoc (Biorad). Arrow-
heads indicate top down: P-MST, GST-Flag-RASSF1A, GST-Flag-
RASSF1AΔSARAH (ΔS), Flag-RASSF1A, Flag-RASSF1AΔSARAH
(ΔS), and GAPDH.
RASSF1A and Nore1 interact with the proapoptotic Ste20
proteinkinaseMST1viatheC-terminus[16,19]throughthe
SARAH domain [32]. The homologue of RASSF1, NORE1
forms a complex with MST1 that mediates a proapoptotic
pathway induced by Ras [18]. Early on, it was reported that
MST1 is a serine/threonine protein kinase that could auto-
phosphorylate itself [47] and later Praskova et al. demon-
strated that MST1 phosphorylates and activates itself,
whereas this autophosphorylation is inhibited when MST1
is bound to RASSF1A and RASSF1C [16]. We show that
the interaction of RASSF1A and RASSF1C with MST1 and
MST2 depends on the C-terminal SARAH domain. Since the
SARAH domain binds the proapoptotic kinases MST1 and
MST2, a deregulation of these kinases may contribute to the
apoptoticrateinthecellswithtruncatedRASSF1A.However,
we could not observe an autophosphorylation of MST1/2
after transfection of RASSF1A and RASSF1AΔSARAH. In
contrast, staurosporine induced strong phosphorylation of
MST1/2. This indicates that RASSF1A-induced apoptosis
observed in A549 cells occurs MST independent, possibly
through the N-terminus of RASSF1A, that associates with
MDM2 and death-domain-associated protein (DAXX) and
contributes to p53 activation in response to DNA damage
[22]. Alternatively, RASSF1A was further linked to apoptosis
through interacting with the microtubule-associated protein
C19ORF5 [48, 49]. Furthermore, Donninger et al. described
RASSF1A to interact with the potential tumor suppressor
Salvador to promote apoptosis independently of Hippo
signaling by modulating p73 [50].
It was demonstrated that RASSF1A colocalizes with the
microtubule network during interphase and is found at the
spindles and centrosomes during mitosis [14, 23]. RASSF1A
binds to tubulin [7], thereby stabilizing microtubules [7, 12–
14] and regulating the mitotic progression. RASSF1A over-
expressionleadstoamitoticarrestatmetaphase[14],toaG1
arrest [51], to a G2/M arrest [52], to a G1 and G2/M arrest
[7],andaprometaphasearrest[23].Thedomainrequiredfor
both microtubule association and stabilization was mapped
to an amino-acid fragment from 120 to 288 [14]. Thus, the
microtubule binding site and the SARAH domain are
diﬀerent [12, 14, 53] and this is consistent with our observa-
tion. Rong et al. showed that the microtubule binding was
lost upon mutation of the phosphorylation site 203 in
RASSF1A [54]. However, we and others did not observe
an altered microtubule binding using phosphomimicking or
nonphosphorylatable mutants of RASSF1A [15, 24].
RASSF1A was also reported to interact with MAP1B
(microtubule-associated protein 1B) and C19ORF5 (chro-
mosome 19 open reading frames 5), both microtubule-asso-
ciated proteins [13, 49, 53]. C19ORF5 is a hyperstabilized
microtubule-speciﬁc binding protein of which accumula-
tion causes mitochondrial aggregation and cell death [48].
Regarding C19ORF5, it was demonstrated that its knock-
down led to mitotic abnormalities [55], that C19ORF5 lo-
calizes to centrosomes, and it was stated that C19ORF5 is re-
quired for the recruitment of RASSF1A to the spindle poles
[53, 55]. Liu et al. reported that RASSF1A caused hyperstabi-
lization of microtubules and the accumulation of C19ORF5
on them [48]. The complex LATS1/MST2/WW45 is found
together with RASSF1A at the centrosome, and it was shown
that defects in this pathway may lead to abnormal mitosis
caused by cytokinesis failure. Thus, RASSF1A may mediate
organization of mitotic spindle poles through the recruit-
ment of MST and LATS to the centrosomes.
In summary, our data indicate that RASSF1A is impor-
tant for several signals, which are frequently altered in tu-
morigenesis, including apoptosis, mitotic spindle organiza-
tion, and proliferation. Our data suggest that other domains
(e.g.,microtubuleassociationdomain)thanSARAHalsosig-
niﬁcantly contribute to the proapoptotic and antiprolifera-
tive function of RASSF1A. Speciﬁc interaction of RASSF1A
with MST/LATS and other binding partners (e.g., RAS,
MDM2, DAXX, C19ORF5, and Salvador) might be impor-
tant in the regulation of proliferation and apoptosis and in
the formation of normal mitotic spindles and processes of
dividing chromosomes by RASSF1A.
Abbreviations
RASSF1A: Ras association domain family 1A
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